During the presentation at the 44th Annual J.P. Morgan Healthcare Conference, CEO Bernard Zovighian outlined Edwards’ sharpened strategy after three years of exclusive focus on Structural Heart. He emphasized accelerated deployment across core platforms—transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and surgical valves—leveraging a streamlined global footprint to speed clinical development and commercial roll-out. Zovighian highlighted ongoing investments in next-generation iterations of each platform, noting that an estimated 250,000 patients worldwide remain untreated each year within these indications. He also underlined the company’s commitment to differentiated product profiles backed by rigorous, world-class clinical evidence to drive adoption and expand addressable markets through 2026 and beyond.

Zovighian reminded investors that the company’s forward-looking statements carry inherent risks, all detailed on Edwards Lifesciences’ SEC filings and website. He reiterated the use of non-GAAP financial measures to track performance, with full reconciliations available online. This transparency framework is designed to support clearer visibility into R&D spend—which grew by 18% year-over-year to $630 million in fiscal 2025—and to contextualize near-term investments against mid-term margin targets of 50% in core Structural Heart operations.

In March 2025, Edwards secured CE Mark approval for its SAPIEN M3 transfemoral transcatheter mitral valve replacement system, marking the first therapy in Europe for patients deemed unsuitable for conventional surgery or repair. The device demonstrated a 92% acute procedural success rate and a 30-day mortality of 3.5% in its pivotal study of 200 high-risk patients. This approval is expected to catalyze initial shipments in key EU markets by mid-2026 and to serve as a springboard for ongoing trials in North America and Asia, where cumulative mitral regurgitation procedures exceed 150,000 annually.